We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
MiNK Therapeutics Inc | NASDAQ:INKT | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.01 | 1.04% | 0.97 | 0.9446 | 0.98 | 0.9845 | 0.9401 | 0.97 | 32,248 | 22:31:05 |
Presentation Details
Title: Peripheral and tissue persistence of agenT-797, an allogeneic iNKT cell-based cell therapy for the treatment of cancer
Presenting Author: Marco Purbhoo, Ph.D., Head of Translational Research, MiNK Therapeutics
Abstract Number: 735
About MiNK Therapeutics
MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. MiNK is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. The company is headquartered in New York, NY. For more information, visit https://minktherapeutics.com/ and our Twitter handle @MiNK_iNKT. Information that may be important to investors will be routinely posted on our website and Twitter.
Investor Contact917-362-1370investor@minktherapeutics.com
Media Contact781-674-4428communications@minktherapeutics.com
1 Year MiNK Therapeutics Chart |
1 Month MiNK Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions